Analyst Bullish on Cogent (COGT) Amid Expected Drug Approval

Cogent Biosciences Inc. (NASDAQ:COGT) is one of the 15 stocks with the biggest hedge fund momentum, after gaining 25 hedge fund holders during the fourth quarter of 2025. On February 18, Piper Sandler analysts raised their price target on Cogent Biosciences Inc. (NASDAQ:COGT) t0 $52 from $39. According to these analysts, who maintained an Overweight rating on Cogent Biosciences Inc. (NASDAQ:COGT), their $13 increase on the price target is justified by the company’s shift toward regulatory approvals and com ...